Related Experiment Videos
Donor age-related differences in PBPC mobilization with rHuG-CSF
J de La Rubia1, M A Díaz, A Verdeguer
1Spanish Group of Allogeneic Peripheral Blood Stem Cell Transplantation, La Fe Hospital, Valencia, Spain. delarubia_jav@gva.es
Transfusion
|March 10, 2001
Summary
Recombinant human granulocyte-colony stimulating factor (rHuG-CSF) effectively mobilizes CD34+ cells in donors under 18, similar to adults. Younger donors required fewer apheresis procedures for adequate cell collection.
Area of Science:
- Hematology
- Transplant Immunology
- Cellular Therapy
Background:
- Limited data exists on recombinant human granulocyte-colony stimulating factor (rHuG-CSF) administration in pediatric donors (<18 years old).
- Understanding mobilization patterns in younger donors is crucial for optimizing stem cell collection procedures.
Purpose of the Study:
- To evaluate the efficacy and safety of rHuG-CSF in mobilizing CD34+ cells in donors under 18 years old.
- To compare outcomes in pediatric donors with adult donors.
Main Methods:
- Retrospective analysis of 61 donors <18 years old (Group A) receiving rHuG-CSF.
- Comparison with 353 adult donors (Group B) from the Spanish National Donor Registry.
- Evaluation of CD34+ cell yield, apheresis requirements, and adverse events.
Main Results:
- Similar CD34+ cell mobilization per kg body weight was observed in both groups (7.6 x 10^6/kg in Group A vs. 6.9 x 10^6/kg in Group B).
- A higher percentage of younger donors (56%) achieved target CD34+ cell counts with one apheresis compared to adults (39%).
- Adverse events were less frequent in the pediatric group (41%) than in the adult group (71%).
Conclusions:
- rHuG-CSF administration is effective in mobilizing CD34+ cells in donors <18 years old, mirroring adult responses.
- Younger age is associated with a reduced need for multiple apheresis sessions to achieve adequate CD34+ cell collection.